Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2463-2467

  Macauley, Shannon L ^a   Stanley, Molly ^a   Caesar, Emily E ^a   Yamada, Steven A ^a   Raichle, Marcus E ^a,b   Perez, Ronaldo ^a   Mahan, Thomas E ^a   Sutphen, Courtney L ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AMYLOID BETA PROTEIN; DIAZOXIDE; GLIBENCLAMIDE; GLUCOSE; LACTIC ACID; PINACIDIL;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE DEPOLARIZATION; ELECTRIC ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIPPOCAMPUS; HYPERGLYCEMIA; IN VIVO STUDY; INTERSTITIAL FLUID; MICRODIALYSIS; MOUSE; NERVE CELL; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANIMAL; DIABETES MELLITUS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HIPPOCAMPUS; HUMANS; HYPERGLYCEMIA; KATP CHANNELS; MICE; MICE, TRANSGENIC; NEURONS;

EID: 84930405360     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79742     Document Type: Article

References (27)

1. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: The challenge of the second century. Sci Transl Med. 2011;3(77): 77sr1.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297(5580): 353-356.
3. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9): 1937-1942.
4. Huang CC, et al. Diabetes mellitus and the risk of Alzheimer's disease: A nationwide populationbased study. PLoS One. 2014;9(1): E87095.
5. Crane PK, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6): 540-548.
6. Morris JK, Vidoni ED, Honea RA, Burns JM, Alzheimer's Disease Neuroimaging Initiative. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging. 2014;35(3): 585-589.
7. Craft S, Cholerton B, Baker LD. Insulin and Alzheimer's disease: Untangling the web. J Alzheimers Dis. 2013;33(suppl 1): S263-S275.
8. Craft S. Alzheimer disease: Insulin resistance and AD - extending the translational path. Nat Rev Neurol. 2012;8(7): 360-362.
9. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2): 147-152.
10. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012;9(1): 35-66.
11. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A. 1998;95(1): 316-321.
12. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011;14(6): 724-738.
13. Bero AW, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14(6): 750-756.
14. Cirrito JR, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58(1): 42-51.
15. Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron. 2005;48(6): 913-922.
16. Yan P, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29(34): 10706-10714.
17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3): E214-E223.
18. Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaqueassociated changes in amyloid-β metabolism and half-life. J Neurosci. 2003;23(26): 8844-8853.
19. Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue β-Amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13(2): 159-170.
20. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A. 1994;91(22): 10625-10629.
21. Uehara T1, Sumiyoshi T, Itoh H, Kurata K. Lactate production and neurotransmitters; evidence from microdialysis studies. Pharmacol Biochem Behav. 2008;90(2): 273-281.
22. Roh JH, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of β-Amyloid in mice with Alzheimer's disease pathology. Sci Transl Med. 2012;4(150): 150ra122.
23. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature. 2006;440(7083): 470-476.
24. Huang CW, Huang CC, Cheng JT, Tsai JJ, Wu SN. Glucose and hippocampal neuronal excitability: Role of ATP-sensitive potassium channels. J Neurosci Res. 2007;85(7): 1468-1477.
25. Dunn-Meynell AA, Rawson NE, Levin BE. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res. 1998;814(1): 41-54.
26. Liu D, et al. The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;22(2): 443-457.
27. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 280-292.